A peptide that is 99% pure today may be 85% pure in six months. Understanding degradation pathways is the difference between a stable product and a liability.

1. Peptides Are Not Small Molecules

Small-molecule drugs are typically stable for years under proper storage. Peptides are not. They are proteins’ smaller cousins, and they share proteins’ vulnerability to chemical degradation. A peptide’s shelf life depends on its amino acid composition, its formulation, and its storage conditions — and the difference between a stable and unstable peptide can be a single amino acid.

This article covers the five major degradation pathways for GLP-1 and other therapeutic peptides, and the stability testing program required to characterize them.

2. The Five Degradation Pathways

2.1 Deamidation

Deamidation is the hydrolysis of asparagine (Asn) or glutamine (Gln) side-chain amides to form carboxylic acids. It is the most common degradation pathway for peptides containing Asn residues.

Mechanism: Asn → cyclic imide intermediate → Asp (aspartic acid) or iso-Asp (isoaspartic acid)

Rate depends on:

• The residue following Asn: Asn-Gly is the fastest (half-life measured in days at neutral pH)
• pH: fastest at pH 7–8; slower at acidic pH
• Temperature: Arrhenius relationship; 10°C increase roughly doubles rate
• Buffer composition: phosphate buffers accelerate deamidation

GLP-1 relevance: Semaglutide contains no Asn residues, but tirzepatide contains Asn²⁷ and retatrutide contains Asn³⁰. These are potential deamidation sites.

Detection: RP-HPLC (deamidated forms are more acidic and elute earlier), LC-MS (+1 Da mass shift), LC-MS/MS (distinguishes Asp from iso-Asp by diagnostic fragment ions).

2.2 Oxidation

Oxidation affects methionine (Met), tryptophan (Trp), cysteine (Cys), and histidine (His) residues.

Common oxidation products:

• Met → Met sulfoxide (+16 Da) → Met sulfone (+32 Da)
• Trp → hydroxytryptophan, N-formylkynurenine, kynurenine
• Cys → disulfide (if free thiol present) or cysteic acid

GLP-1 relevance: Semaglutide contains Met⁸, Trp²⁵, and Phe²². Tirzepatide contains Met¹⁴ and Trp²⁵. Retatrutide contains Met¹⁴ and Trp²⁵. Met oxidation is the primary oxidative degradation pathway for all three.

Detection: RP-HPLC (oxidized forms are more polar), LC-MS (+16 Da for sulfoxide), and specific peptide mapping after enzymatic digestion.

2.3 Aggregation

Peptide aggregation occurs when peptide molecules associate through hydrophobic interactions, hydrogen bonding, or β-sheet formation. Aggregates can be soluble (oligomers) or insoluble (fibrils, precipitates).

Risk factors:

• High peptide concentration (>5 mg/mL)
• Hydrophobic amino acid content
• Agitation (shaking, stirring)
• Air-water interface exposure
• Temperature cycling

GLP-1 relevance: GLP-1 peptides are formulated at relatively high concentrations (2.5–20 mg/mL for commercial products) and are prone to aggregation. The fatty acid side chain in semaglutide, tirzepatide, and retatrutide promotes albumin binding but also increases self-association tendency.

Detection: Size-exclusion chromatography (SEC), dynamic light scattering (DLS), UV-Vis turbidity (350 nm), thioflavin T fluorescence (for amyloid-like fibrils).

2.4 Isomerization

Aspartic acid (Asp) residues can isomerize to isoaspartic acid (iso-Asp) via the same cyclic imide intermediate as deamidation. This changes the peptide backbone structure (inserting a methylene group into the backbone) without changing the molecular mass.

Detection: Iso-Asp is invisible to intact mass analysis. It requires peptide mapping with LC-MS/MS, where iso-Asp produces diagnostic fragment ions different from Asp. Enzymatic methods (protein isoaspartyl methyltransferase, PIMT) can also quantify iso-Asp.

2.5 Hydrolysis (Peptide Bond Cleavage)

Peptide bonds can hydrolyze, particularly at Asp-Pro bonds (acid-labile) or under extreme pH/temperature conditions. This produces truncated peptide fragments.

Detection: RP-HPLC (fragments have different retention times), LC-MS (mass corresponding to fragment), SDS-PAGE (for larger fragments).

3. Stability Testing Protocol

A comprehensive stability program for therapeutic peptides includes:

3.1 Long-Term Stability

• Conditions: 5°C ± 3°C (refrigerated), as per labeled storage
• Duration: Minimum 12 months, with time points at 0, 3, 6, 9, 12 months
• Tests: Appearance, pH, purity (HPLC), identity (LC-MS), peptide content, particulate matter, endotoxin

3.2 Accelerated Stability

• Conditions: 25°C ± 2°C / 60% RH ± 5% RH
• Duration: 6 months, with time points at 0, 1, 2, 3, 6 months
• Purpose: Identify degradation pathways and predict long-term behavior
• Tests: Same as long-term, plus degradation product identification by LC-MS/MS

3.3 Stress Testing (Forced Degradation)

Stress testing is conducted to identify degradation pathways and develop stability-indicating methods:

3.4 Stability-Indicating Method Development

A stability-indicating analytical method must:

• Resolve the parent peptide from all degradation products
• Have acceptable specificity, linearity, precision, and accuracy
• Be validated per ICH Q2(R1) guidelines
• Include mass spectrometry confirmation of degradation product identity

4. Practical Implications for Buyers and Compounders

4.1 Expiration Dating

A peptide’s expiration date is only valid if:

• It is stored under the labeled conditions
• The container closure system is intact
• The stability study was conducted on the same formulation and container

A peptide labeled “24 months at 2–8°C” that is shipped at ambient temperature for 5 days has effectively consumed a significant portion of its shelf life. The Q10 rule (a 10°C increase doubles degradation rate) means 5 days at 25°C is roughly equivalent to 20 days at 5°C.

4.2 Reconstituted Product Stability

Once reconstituted, peptide stability changes dramatically. Bacteriostatic water may contain preservatives (benzyl alcohol) that interact with the peptide. The reconstituted solution is typically stable for:

• 30 days at 2–8°C (for most GLP-1 peptides)
• 7–14 days at room temperature

These are general estimates; actual stability must be determined for each formulation.

5. Conclusion

Peptide degradation is not a theoretical concern — it is a predictable, measurable process that directly affects product quality and patient safety. A rigorous stability program, including long-term, accelerated, and stress testing with stability-indicating methods, is essential for any organization that stores, ships, or compounds peptide products. Without it, “99% purity” is a snapshot in time, not a guarantee of quality.